Search results
Car T-Cell Therapy
WNDU 16 South Bend· 1 day agoMedical experts call it a ‘breakthrough’ and ‘gamechanger’ when it comes to cancer treatment. “Immunotherapy has really come on as quite an advance in...
Can multiple myeloma be cured? Treatments and outlook
Medical News Today· 6 days agoConsolidation: This is only if a person is to receive a stem cell transplant. Maintenance: This...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
WRBL Columbus· 8 hours ago...leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors Generated $95 million in milestone and upfront...Astellas collaboration and $45 million from continued execution in the Company's CAR-T partnership with Roche Presented promising early data...
Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of...
WRBL Columbus· 4 days agoOn May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal of Science, published a research paper titled "Single-cell analysis of anti-BCMA ...
Kite and Arcellx to start Phase 3 trial for myeloma therapy By Investing.com
Investing.com· 5 days agoAnito-cel, which utilizes Arcellx’s novel D-Domain binder, is a BCMA CAR T-cell therapy, a type of...
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
Clinical Trials Arena via Yahoo Finance· 5 days agoKite, a Gilead Company, and Arcellx have announced plans to commence a Phase III clinical trial of...
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Morningstar· 5 days agoKite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple ...
Breakthrough therapies are saving lives, but can we afford them?
Medical Xpress· 1 day agoLast month, Stanford became the first hospital in the nation to use a new $515,000 cell therapy to...
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
GuruFocus.com via Yahoo Finance· 4 days agoFDA, highlighting its potential therapeutic importance. Additionally, Arcellx is advancing its novel CAR T therapy platforms, which are ...
Fate Therapeutics Inc (FATE) Q1 2024 Earnings: Mixed Financial P
Guru Focus· 4 days agoThe clinical-stage biopharmaceutical company, known for its innovative programmed cellular immunotherapies for cancer and autoimmune disorders, reported a mix of financial challenges and significant ...